Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

The Lancet Infectious Diseases

Volumn 17, Issue 7, 2017, Pages 726-734

  Gutiérrez Gutiérrez, Belén ^a   Salamanca, Elena ^a   de Cueto, Marina ^a   Hsueh, Po Ren ^b   Viale, Pierluigi ^c   Paño Pardo, José Ramón ^d,e   Venditti, Mario ^f   Tumbarello, Mario ^g   Daikos, George ^h   Cantón, Rafael ⁱ   Doi, Yohei ^j   Tuon, Felipe Francisco ^k   Karaiskos, Ilias ^l   Pérez Nadales, Elena ^m,n   Schwaber, Mitchell J ^o,p   Azap, Özlem Kurt ^q   Souli, Maria ^r   Roilides, Emmanuel ^s   Pournaras, Spyros ^t   Akova, Murat ^u   Pérez, Federico ^v   Bermejo, Joaquín ^w   Oliver, Antonio ^x   Almela, Manel ^y   Lowman, Warren ^z   Almirante, Benito ^aa   Bonomo, Robert A ^v,ab   Carmeli, Yehuda ^o,p   Paterson, David L ^ac   Pascual, Alvaro ^a,ad   Rodríguez Baño, Jesús ^a,ad   del Toro, M D ^ae   Galvez J ^ae   Falcone, M ^ae   Russo, A ^ae   Giamarellou, H ^ae   Trecarichi, E M ^ae   Losito, A R ^ae   Garcia Vazquez E ^ae   Hernandez A ^ae   Gomez J ^ae   Bou, G ^ae   Iosifidis, E ^ae   Prim, N ^ae   Navarro, F ^ae   Mirelis, B ^ae   Skiada, A ^ae   Origuen J ^ae   Juan, R San ^ae   Fernandez Ruiz M ^ae   Larrosa, N ^ae   Puig Asensio, M ^ae   Cisneros, J M ^ae   Molina, J ^ae   Gonzalez V ^ae   Rucci, V ^ae   de Gopegui, E Ruiz ^ae   Marinescu, C I ^ae   Martinez Martinez L ^ae   Farinas M C ^ae   Cano, M E ^ae   Gozalo, M ^ae   Mora Rillo, M ^ae   Francisco, C Navarro San ^ae   Pena C ^ae   Gomez Zorrilla S ^ae   Tubau, F ^ae   Tsakris, A ^ae   Zarkotou, O ^ae   Antoniadou, A ^ae   Poulakou, G ^ae   Pitout, J ^ae   Virmani, D ^ae   Torre Cisneros, J ^ae   Guzman Puche J ^ae   Helvaci, O ^ae   Sahin, A O ^ae   Pintado, V ^ae   Ruiz, P ^ae   Bartoletti, M ^ae   Giannella, M ^ae   Tacconelli, E ^ae   Riemenschneider, F ^ae   Calbo, E ^ae   Badia, C ^ae   Xercavins, M ^ae   Gasch, O ^ae   Fontanals, D ^ae   Jove E ^ae   more..

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN IIS ARAGÓN   (Spain)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

^h UNIVERSITY OF ATHENS   (Greece)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j UNIVERSITY OF PITTSBURGH   (United States)

^k FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^l IASO GENERAL HOSPITAL   (Greece)

^m Maimonides Institute for Research in Biomedicine of Cordoba   (Spain)

ⁿ UNIVERSITY OF CÓRDOBA   (Spain)

^o TEL AVIV UNIVERSITY   (Israel)

^p MINISTRY OF HEALTH   (Israel)

^q BASKENT UNIVERSITY   (Turkey)

^r NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^s Aristotle University and Hippokration General Hospital   (Greece)

^t UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^u HACETTEPE UNIVERSITY   (Turkey)

^v LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^w HOSPITAL ESPAÑOL   (Argentina)

^x HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^y HOSPITAL CLÍNIC   (Spain)

^z University of the Witwatersrand   (South Africa)

^aa HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^ab CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ac UNIVERSITY OF QUEENSLAND   (Australia)

^ad UNIVERSITY OF SEVILLE   (Spain)

^ae NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; BLOODSTREAM INFECTION; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; TREATMENT DURATION; BACTEREMIA; COMBINATION DRUG THERAPY; DRUG EFFECTS; KLEBSIELLA INFECTIONS; MICROBIOLOGY; PROCEDURES; RISK FACTOR;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85018723782     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30228-1     Document Type: Article

References (22)

1. Tzouvelekis, LS, Markogiannakis, A, Psichogiou, M, Tassios, PT, Daikos, GL, Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 25 (2012), 682–707.
2. Falagas, ME, Tansarli, GS, Karageorgopoulos, DE, Vardakas, KZ, Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 20 (2014), 1170–1175.
3. Fraenkel-Wandel, Y, Raveh-Brawer, D, Wiener-Well, Y, Yinnon, AM, Assous, MV, Mortality due to blaKPC Klebsiella pneumoniae bacteraemia. J Antimicrob Chemother 71 (2016), 1083–1087.
4. Tumbarello, M, Viale, P, Viscoli, C, et al. Predictors of mortality in bloodstream infections caused by KPC-producing Klebsiella pneumoniae: importance of combination therapy. Clin Infect Dis 55 (2012), 943–950.
5. Qureshi, ZA, Paterson, DL, Potoski, BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56 (2012), 2108–2113.
6. Daikos, GL, Tsaousi, S, Tzouvelekis, LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58 (2014), 2322–2328.
7. Palacios-Baena, ZR, Oteo, J, Conejo, C, et al. Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. J Infect 72 (2016), 152–160.
8. Lee, CR, Lee, JH, Park, KS, Kim, YB, Jeong, BC, Lee, SH, Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods. Front Microbiol, 7, 2016, 895.
9. Paul, M, Carmeli, Y, Durante-Mangoni, E, Mouton, JW, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69 (2014), 2305–2309.
10. Gomez-Simmonds, A, Nelson, B, Eiras, DP, et al. Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 60 (2016), 3601–3607.
11. Rodríguez-Baño, J, Cisneros, JM, Cobos-Trigueros, N, et al. Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enferm Infecc Microbiol Clin 33 (2015), 337.e1–337.e2.
12. Gutiérrez-Gutiérrez, B, Salamanca, E, de Cueto, M, et al. A predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae. Mayo Clin Proc 91 (2016), 1362–1371.
13. Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR, A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chron Dis 40 (1987), 373–383.
14. Hilf, M, Yu, VL, Sharp, J, Zuravleff, JJ, Korvick, JA, Muder, RR, Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 87 (1989), 540–546.
15. Levy, MM, Fink, MP, Marshall, JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference. Crit Care Med 31 (2003), 1250–1256.
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute document M100-S22, 2012, Clinical and Laboratory Standards Institute, Wayne.
17. Tumbarello, M, Trecarichi, EM, De Rosa, FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70 (2015), 2133–2143.
18. Daikos, GL, Markogiannakis, A, Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?. Clin Microbiol Infect 17 (2011), 1135–1141.
19. Viale, P, Giannella, M, Lewis, R, Trecarichi, EM, Petrosillo, N, Tumbarello, M, Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther 11 (2013), 1053–1063.
20. Zarkotou, O, Pournaras, S, Tselioti, P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17 (2011), 1798–1803.
21. Falcone, M, Russo, A, Iacovelli, A, et al. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect 22 (2016), 444–450.
22. Dickstein, Y, Leibovici, L, Yahav, D, et al. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open, 6, 2016, e009956.